


References


Towards identification of subsets of patients with multiple myeloma who benefit from high-dose chemotherapy

Haematologica has recently published a review article on treatment of multiple myeloma, an analysis of optimization of peripheral blood progenitor cell autologous transplantation in this condition and the GITM O experience in this field. Previous papers dealt with treatment of multiple myeloma.

In this issue, Boccadoro et al. report on a study comparing high-dose vs conventional chemotherapy. Their findings strongly suggest the superiority of high-dose chemotherapy for multiple myeloma patients below 55, at least in terms of complete remission and event-free survival. Although this observation needs to be confirmed by other independent studies, it represents a step forward towards identification of subsets of patients who would be best candidates for high-dose chemotherapy.

References


2. Harousseau JL Optimizing peripheral blood progeni-


